Rockefeller University

This early study tested a lab-made antibody called 3BNC117-LS in 43 people, some with HIV and some without. The goal was to see if it is safe and how long it stays in the body. If it works, this antibody might one day help control HIV with less frequent dosing.

This early-stage trial tested whether a single infusion of two long-acting antibodies plus repeated injections of an immune-stimulating drug can keep HIV under control after people stop their daily antiretroviral therapy. Twenty-eight adults with well-controlled HIV participated.…

This early-phase study tested whether two lab-made antibodies (3BNC117 and 10-1074) could help people with HIV control the virus after stopping their daily antiretroviral therapy (ART). Twenty-six participants on stable ART received seven infusions of the antibodies, then paused …

This pilot study tested a 10-week compassion-based resiliency training (CBRT) program in 22 African American adults to see if it could help reduce stress from racism. The program taught mindfulness, self-awareness, and stress-reduction techniques. Researchers measured stress, moo…

This pilot study tests a new technology called inDrop RNA-Seq to analyze individual immune cells in detail. Researchers will use it to study how healthy adults respond to the yellow fever vaccine, which is known to be very effective. The goal is to identify the specific cell type…

This study looked at how a short course of antibiotics changes the nerve and glia cells in the lower gut of 10 healthy adults. Researchers took colon tissue samples before and after antibiotic treatment to count these cells and measure gene activity. The goal was to understand if…